Company Description
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.
Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema.
It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
| Country | Australia |
| Founded | 1984 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Frederic Guerard |
Contact Details
Address: 650 Chapel Street, Suite 0403, Level 4 South Yarra, VIC 3141 Australia | |
| Phone | 61 3 9826 0399 |
| Website | opthea.com |
Stock Details
| Ticker Symbol | OPT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $13.50 |
| CIK Code | 0001815620 |
| CUSIP Number | 68386J208 |
| ISIN Number | US68386J2087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Frederic Guerard | Chief Executive Officer |
| Daniel Geffken | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2024 | 6-K | Report of foreign issuer |
| Sep 10, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Sep 5, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Aug 30, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Aug 30, 2024 | 6-K | Report of foreign issuer |
| Aug 8, 2024 | 6-K | Report of foreign issuer |
| Jul 17, 2024 | 6-K | Report of foreign issuer |
| Jul 15, 2024 | 6-K | Report of foreign issuer |